Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1706-1712

  Østergaard, Christian ^a   Sørensen, Tina Klitmøller ^a   Knudsen, Jenny Dahl ^a   Frimodt Møller, Niels ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 7 (2,6 DIMETHYL 4 PYRIDYL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; 8 METHOXYQUINOLONE DERIVATIVE; CEFTRIAXONE; CLINAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMAFLOXACIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL MENINGITIS; CONTROLLED STUDY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0031807605     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1706     Document Type: Article

References (33)

1. Bradley, J. S., and W. M. Scheld. 1997. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clin. Infect. Dis. 24:S213-S221.
2. Cavet, M. E., M. West, and N. L. Simmons. 1997. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 121:1567-1578.
3. Dacey, R. G., and M. A. Sande. 1974. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob. Agents Chemother. 6:437-441.
4. Dalhoff, A., U. Petersen, and R. Endermann. 1996. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy (Basel) 42:410-425.
5. Decazes, J. M., J. Mohler, A. Bure, J. M. Vallois, A. Meulemans, and J. Modai. 1989. Pharmacokinetics of fleroxacin and its metabolites in serum, cerebrospinal fluid, and brain of rabbits with and without experimental Escherichia coli meningitis. Rev. Infect. Dis. 11:1208-1209.
6. Drion, N., M. Lemaire, J. M. Lefauconnier, and J. M. Scherrmann. 1996. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J. Neurochem. 67:1688-1693.
7. Durand, M. L., S. B. Calderwood, and D. J. Weber. 1993. Acute bacterial meningitis in adults: a review of 493 episodes. N. Engl. J. Med. 328:21-28.
8. Friedland, I. R., M. Paris, S. Ehrett, S. Hickey, K. Olsen, and G. H. McCracken. 1993. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 37:1630-1636.
9. Frimodt-Moller, N. 1988. Correlation of in vitro activity and pharmacokinetic parameters with effect in vivo for antibiotics. Observations from experimental pneumococcus infection in mice. Dan. Med. Bull. 35:422-437.
10. Frimodt-Moller, N., M. W. Bentzon, and V. F. Thomsen. 1987. Experimental pneumococcus infection in mice: comparative in vitro and in vivo effect of cefuroxime, cefotaxime and ceftriaxone. Acta Pathol. Microbiol. Immunol. Scand. Sect. B 95:261-267.
11. Ito, T., I. Yano, K. Tanaka, and K. I. Inui. 1997. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J. Pharmacol. Exp. Ther. 282:955-960.
12. John, C. C. 1997. Treatment failure with use of a third-generation cephalosporin for penicillin resistant pneumococcal meningitis: case report and review. Clin. Infect. Dis. 18:188-193.
13. Kim, Y. S., Q. X. Liu, L. L. Chow, and M. G. Tauber. 1997. Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1186-1189.
14. Klugman, K. P., and T. Capper. 1997. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin. J. Atimicrob. Chemother. 40:797-802.
15. Kubitza, D., H. H. Stass, W. Wingender, and J. Kuhlmann. 1996. BAY 12-8039, a new 8-methoxyquinolone: safety, tolerability and steady state pharmacokinetics in healthy male volunteers, abstr. F25, p. 104. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Lutsar, I., A. Ahmed, I. R. Friedland, M. Trujillo, L. Wubbel, K. Olsen, and G. H. McCracken, Jr. 1997. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 41:2414-2417.
17. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed., p. 10-13. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Nau, R., T. Schmidt, K. Kaye, J. L. Froula, and M. G. Tauber. 1995. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. 39:593-597.
19. Ooie, T., H. Suzuki, T. Terasaki, and Y. Sugiyama. 1996. Comparative distribution of quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs. J. Pharmacol. Exp. Ther. 278:590-596.
20. Ooie, T., T. Terasaki, H. Suzuki, and Y. Sugiyama. 1997. Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system. Drug Metab. Dispos. 25:784-789.
21. Paris, M. M., S. M. Hickey, M. Trujillo, S. Shelton, and G. H. McCracken. 1995. Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 39:1243-1246.
22. Sande, M. A., O. M. Korzeniowski, G. M. Allegro, R. O. Brennan, O. Zak, and W. M. Scheld. 1981. Intermittent or continuous therapy of experimental meningitis due to Streptococcus pneumoniae in rabbits: preliminary observations on the post-antibiotic effect in vivo. Rev. Infect. Dis. 3:98-109.
23. Scheld, W. M. 1989. Quinolone therapy for infections of the central nervous system. Rev. Infect. Dis. 11(Suppl. 5)S1194-S1202.
24. Schlech, W. F. III, J. I. Ward, J. D. Band, A. Hightower, D. W. Fraser, and C. V. Broome. 1985. Bacterial meningitis in the United States, 1978 through 1981. The National Bacterial Meningitis Surveillance Study. JAMA 253: 1749-1754.
25. Schmidt, T., and M. G. Tauber. 1993. Pharmacodynamics of antibiotics in the therapy of meningitis: infection model observations. J. Antimicrob. Chemother. 31(Suppl. D):61-70.
26. Spector, R., and A. V. Lorenzo. 1974. Inhibition of penicillin transport from the cerebrospinal fluid after intracisternal inoculation of bacteria. J. Clin. Invest. 54:316-325.
27. Stass, H., U. Schühly and W. Wingender. 1997. Pharmacokinetics, safety and tolerability of 600 mg BAY 12-8039 administered once daily over 10 days, abstr. 387, p. 87. In Abstracts of the 8th European Congress of Clinical Microbiology and Infectious Diseases.
28. Tauber, M. G., C. A. Doroshow, C. J. Hackbarth, M. G. Rusnak, T. A. Drake, and M. A. Sande. 1984. Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J. Infect. Dis. 149:568-574.
29. Tauber, M. G., S. Kunz, O. Zak, and M. A. Sande. 1989. Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. 33:418-423.
30. Tauber, M. G., O. Zak, W. M. Scheld, B. Hengstler, and M. A. Sande. 1984. The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. J. Infect. Dis. 149: 575-583.
31. Tomasz, A. 1997. Antibiotic resistance in Streptococcus pneumoniae. Clin. Infect. Dis. 24:S85-S88.
32. Wenger, J. D., A. W. Hightower, R. R. Facklam, S. Gaventa, and C. V. Broome. 1990. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. J. Infect. Dis. 162:1316-1323.
33. Woodcock, J. M., J. M. Andrews, F. J. Boswell, N. P. Brenwald, and R. Wise. 1997. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:101-106.